Valley Cottage, NY, January 27, 2016 --(PR.com
)-- Future Market Insights (FMI) delivers key insights on the global peptide therapeutics market in its upcoming outlook titled, “Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020.” In terms of revenue, the global peptide therapeutics market is projected to register a healthy CAGR of 2.9% over the forecast period owing to various factors, which FMI analysis highlights and offers detailed insights and forecasts.
The market is segmented based on disease indications, method of drug administration and regions. The overall market has been segmented broadly into 10 disease indications such as cancer, CNS, cardiovascular, respiratory, gastro-intestinal, haemolytic, metabolic disorders, infections, acromegaly, and others. Cancer and respiratory diseases are the most disease indications affecting the global population. As such, it is worth noting that the respiratory disease segment is expected to grow at a very high CAGR of 54.8% over the period 2015-2020. The prime factors for such a phenomena are rising levels of pollution all across the world as globalisation continues its charm. Another alarming factor is the rising rate of cancers, primarily lung and skin, leading to greater demand peptide-based drugs. The cancer segment is expected to increase in value from US$ 6,383.8Mn in 2014 to US$ 7,965.7 Mn by 2020 expanding at a CAGR of 3.0% over the forecast period.
Browse the full "Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020" market research report at http://www.futuremarketinsights.com/reports/peptide-therapeutics-market
To provide deeper insight into drug delivery channels, the report has also been segmented by routes of drug administration such as oral and parenteral. It has been observed and validated that oral drug administration is much preferred over parenteral method of administration due to ease of administration and patient comfort. However, in extreme stages of critical diseases the parenteral route is preferred.
In terms of drug classes, the generic peptides market is estimated to witness substantial growth in the next few years. Several peptide blockbusters such as glatiramer acetate, bivalirudin, teriparatide, bortezomib and exenatide would lose exclusivity by 2020. Currently, generic drugs account for close to one-third of the total peptide therapeutics market.
The primary barriers in the market include absence of uniformed safety standards and guidance documents, for peptides. This impacts the lack of standards to define the level of impurities permissible in peptide therapeutics. Added to this is an increased level of complexity in the chemical structure of peptides. These factors are expected to affect the popularity of peptides as a drug class over the forecast.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1038
The primary trend in the peptide therapeutics market is an increase in dependence in supply of active pharmaceutical ingredients harnessing in-house capabilities of big drug makers. Other trends include harnessing shorter turnaround times for faster market capitalization, requirement of highly skilled personnel for the drug manufacturing process.
This report assesses trends driving growth of each segment on global as well as regional levels, and offers potential strategic recommendations that could prove useful to drug makers planning to penetrate or enter the market. North America is estimated to dominate the peptide therapeutics market with maximum market share by end of 2015. Among emerging markets, Asia Pacific and Latin America are estimated to witness high CAGRs over the forecast period.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1038
Some key players identified in the global peptide therapeutics market report include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, Eli Lilly & Co., Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, Polypeptide Group, Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals Limited. We have discussed individual strategies followed by these companies in terms of enhancing drug portfolios, market consolidation and drug innovation pipelines. The report has been concluded with strategic recommendations for players already present in the market and also new players planning to enter the market, which could help them in the long run.